Granted its not an apple versus apple comparison.....but its not an apple versus a loaf of bread either.

Both are Biotech, both are publicly traded albeit on different exchanges. Both have trials going on for different diseases.....RVX focused more on CVD and related ailments, Ziopharm on Cancer.

FWIW Ziopharm's Cooper came on board there last year when the PPS was around $11.00, now a year later....its in and around $7. Not the kind of performance I would imagine that shareholders expect out of a guy making $12 million+ USD.

Obviously Ziopharm is a poor benchmark. How many early stage Biotechs have CEO's earning more than the top dog at a company like Novartis?

After you factor in the exchange DM is pulling in somewhere between 500 and 600K $USD per year.....and I would wager that compares very well with others development stage biotech CEOs.